Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Lumexa Imaging Q1 2026 Earnings Call - Advanced Modalities Surge as Weather and Seasonality Temporarily Dampen EBITDA
Lumexa Imaging delivered Q1 2026 results that aligned with management’s expectations, highlighting a strategic pivot toward high-margin advanced imaging modalities that drove a 7% year-over-year growt...
- Consolidated revenues grew 3% year-over-year to $253 million, while system-wide revenue growth reached 4%, with two-thirds driven by volume and one-third by rate increases.
- Advanced modality volumes surged 7% year-over-year, with PET leading at 23.1% growth and MRI rising 8.2%, signaling a successful strategic shift toward higher-reimbursement services.
- Adjusted EBITDA remained flat at $51.2 million, impacted by approximately $4 million in weather-related volume softness and enhanced seasonality that suppressed early-year scan volumes.
- +7 more takeaways
Capricor Therapeutics Q1 2026 Earnings Call - Lawsuit Against NS Pharma Signals Push for Independent DMD Launch
Capricor Therapeutics is positioning for an independent commercial launch of deramiocel for Duchenne muscular dystrophy after filing a lawsuit to rescind its distribution agreement with NS Pharma. CEO...
- Capricor filed a lawsuit on May 7, 2026, to rescind its U.S. distribution agreement with NS Pharma and Nippon Shinyaku, seeking a preliminary injunction to distribute deramiocel independently.
- The BLA for deramiocel to treat Duchenne muscular dystrophy is under active FDA review with a PDUFA target date of August 22, 2026.
- NS Pharma refused to renegotiate the pricing structure, which Capricor states would create hundreds of thousands of dollars in reimbursement shortfalls per dose for providers.
- +7 more takeaways
Astronics Q1 2026 Earnings Call - Record Bookings and Backlog Drive Raised Full-Year Outlook
Astronics delivered a record-breaking start to 2026, with Q1 revenue of $231 million and bookings of $290 million, pushing the backlog to an all-time high of $734 million. The company raised its full-...
- Record Q1 Bookings and Backlog: Bookings hit a record $290 million with a 1.26 book-to-bill ratio, pushing the backlog to an all-time high of $734 million, signaling strong near-term demand.
- Raised Full-Year Guidance: Management increased 2026 revenue guidance to $970 million–$1 billion, up from the previous range of $950 million–$990 million, reflecting organic growth momentum.
- Strong Q1 Revenue and Earnings: Revenue reached $231 million (high end of guidance), up 12% year-over-year. Adjusted EPS rose 34% to $0.59, and adjusted net income grew 32.6% to $22.5 million.
- +7 more takeaways
Spectral AI Q1 2026 Earnings Call - DeepView FDA Clearance Nears, $31.7M BARDA Award Drives 2027 Revenue
Spectral AI reported a solid start to 2026, driven by a $31.7 million acceleration in BARDA funding and continued progress on its DeepView burn assessment system. The company delivered a prototype for...
- DeepView FDA De Novo Application Status: Management remains confident in receiving FDA clearance before the end of Q2 2026, following an active dialogue and additional information requests since the June 2025 submission.
- Commercialization Timeline: The company aims to commercialize the DeepView system for the burn indication by the end of 2026, with initial sales targeted for late 2026 in international markets (U.K., Australia, GCC) pending expanded UKCA labeling.
- $31.7 Million BARDA Award: Spectral AI secured $31.7 million in advanced funding from BARDA in March 2026, which includes a no-cost extension and acceleration of Phase II. This funding supports feature design and procurement of up to 30 devices for burn centers and trauma departments.
- +9 more takeaways
Electromed, Inc. Q3 FY2026 Earnings Call - Revenue Surges 18%, Operating Income Jumps 76% on Bronchiectasis Push
Electromed delivered a standout third quarter of fiscal 2026, posting revenue growth of 18.4% to $18.6 million and a dramatic 76% expansion in operating income to $3.8 million. The company is riding a...
- Revenue grew 18.4% year-over-year to $18.6 million, marking the 14th consecutive quarter of top-line expansion.
- Operating income surged 76% to $3.8 million, while diluted EPS rose 67% to $0.35, showcasing significant operating leverage.
- Direct home care revenue climbed 18.6% to $16.7 million, driven by higher revenue per representative and an expanded sales force.
- +11 more takeaways
National CineMedia Q1 2026 Earnings Call - Attendance Surge and Programmatic Growth Offset by Olympic Budget Shifts
National CineMedia navigated a complex first quarter shaped by the Winter Olympics and a calendar shift, yet delivered revenue and adjusted OIBDA within guidance. Attendance across the network jumped ...
- Total revenue of $34 million and adjusted OIBDA of negative $10.5 million landed within guidance, reflecting typical seasonality, Winter Olympics competition, and a one-week fiscal calendar shift.
- Domestic box office attendance across NCM's network surged 15% year-over-year to 83 million, driven by Q4 tentpole carryover and late-quarter acceleration from Project Hail Mary and early Super Mario Bros. contributions.
- National advertising revenue was flat year-over-year at $27.5 million, with legacy network growth of 2% offset by Spotlight non-renewals and Olympic-driven budget shifts in March.
- +7 more takeaways
Velo3D Q1 2026 Earnings Call - Rapid Production Solutions Drive 48% Revenue Growth and 17% Gross Margin
Velo3D reported a strong first quarter in 2026, with revenue surging 48% year-over-year to $13.8 million, driven by accelerating adoption of its Rapid Production Solutions (RPS) and increased system s...
- Revenue surged 48% year-over-year to $13.8 million, with sequential growth of 46% from Q4 2025, reflecting strong demand across defense and commercial aerospace.
- Gross margin turned positive at 17.2%, a massive improvement from 7.5% in Q1 2025 and negative 73.6% in Q4 2025, driven by higher utilization and manufacturing efficiency.
- Rapid Production Solutions (RPS) now represent approximately 25% of total revenue and account for roughly half of the $30 million backlog, signaling a shift toward recurring, high-margin production contracts.
- +7 more takeaways
Fold Holdings Q1 2026 Earnings Call - Credit Card Launch Accelerates Ecosystem Play
Fold Holdings reported a challenging Q1 2026 as Bitcoin's 50% drawdown from October 2025 pressured transaction volumes and revenues. Despite a 31% year-over-year drop in transaction volumes and a 21% ...
- Bitcoin Price Shock: Q1 2026 operating environment was defined by Bitcoin falling nearly 50% from its October 2025 all-time high, directly pressuring consumer risk appetite and transaction volumes.
- Transaction Volumes Down 31%: Year-over-year transaction volumes dropped 31% in Q1 2026, reflecting the broader industry-wide pullback in trading activity and consumer engagement.
- Revenues Decline 21%: Total revenues fell 21% year-over-year, though the company noted that February 2026 marked a bottom across core KPIs with early signs of a rebound.
- +12 more takeaways
Paysign Q1 2026 Earnings Call - Pharma Revenue Surpasses Plasma as Operating Leverage Drives Record Profitability
Paysign delivered its strongest first quarter in company history, with revenue surging 50.8% to $28 million and net income more than doubling to $5.4 million. The inflection point is structural. Pharm...
- Revenue grew 50.8% year-over-year to $28 million, exceeding the high end of the $27 million to $27.5 million guidance range.
- Net income more than doubled to $5.4 million, a 110% increase from the prior year period, while adjusted EBITDA surged 113% to $10.6 million.
- Operating margins expanded by 1,040 basis points to 23.8%, demonstrating significant operating leverage as costs grew well below revenue.
- +7 more takeaways
Resideo Technologies Q1 2026 Earnings Call - Outperformance Amidst Macro Uncertainty and Separation Progress
Resideo delivered a strong first quarter in 2026, surpassing the high end of its outlook across all key metrics. Total net revenue grew 8% year-over-year to $1.9 billion, while adjusted EBITDA surged ...
- Total net revenue grew 8% year-over-year to $1.9 billion, exceeding the high end of the Q1 2026 outlook range.
- Adjusted EBITDA surged 20% year-over-year to $215 million, driven by revenue outperformance and a $35 million benefit from the terminated indemnification agreement.
- Adjusted EPS of $0.65 beat the high end of the outlook range, up from $0.63 in the prior year period.
- +7 more takeaways